Azacitidine for the treatment of relapsed and refractory AML in older patients. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Itzykson, Raphael; Thépot, Sylvain; Berthon, Céline; Delaunay, Jacques; Bouscary, Didier; Cluzeau, Thomas; Turlure, Pascal; Prébet, Thomas; Dartigeas, Caroline; Marolleau, Jean-Pierre; Recher, Christian; Plantier, Isabelle; Stamatoullas, Aspasia; Devidas, Alain; Taksin, Anne-Laure; Guièze, Romain; Caillot, Denis; Vey, Norbert; Adès, Lionel; Ifrah, Norbert; Dombret, Hervé; Fenaux, Pierre; Gardin, Claude
• Is Part Of: Leukemia research. Volume 39:Issue 2(2015:Feb.)
• Page Start: 124
• Page End: 130
• Publication Date: 2015-02
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2014.11.009
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0080"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Azacitidine is feasible in relapsed/refractory AML patients older than 50 years.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Overall response rate was 17% including 10% complete remissions.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Median overall survival was 8.4 months.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Outcome was better in patients with intermediate risk cytogenetics and few peripheral blasts.</p> </list-item> </list> </p> </sec> </abstract>